Free
Clinical Science  |   May 1996
In Vitro sup 31 Phosphorus-Magnetic Resonance Spectroscopy of Muscle Extracts in Malignant Hyperthermia-susceptible Patients
Author Notes
  • (Payen) Research Assistant of Anesthesiology and INSERM, The University of Grenoble School of Medicine.
  • (Fouilhe, Sam-Lai) Research Assistant of INSERM, The University of Grenoble School of Medicine.
  • (Remy, Dupeyre) Research Fellow of INSERM, The University of Grenoble School of Medicine.
  • (Mezin) Biologist, Cellular Pathology, The University of Grenoble School of Medicine.
  • (Halsall) Research Fellow, Malignant Hyperthermia Unit. The University of Leeds School of Medicine.
  • (Stieglitz) Professor of Anesthesiology, The University of Grenoble School of Medicine.
  • Received from the Department of Anesthesia, the Department of Cellular Pathology, and INSERM U438, Albert Michallon Hospital, Grenoble, France, and the Malignant Hyperthermia Unit, St. James's University Hospital, Leeds, United Kingdom. Submitted for publication August 18, 1995. Accepted for publication January 8, 1995. Supported by a grant from the Association Francaise contre les Myopathies.
  • Address reprint requests to Dr. Payen: INSERM U438, Pavillon B, Hopital A. Michallon, BP 217, CHU Grenoble, 38043 Grenoble Cedex 09, France.
Article Information
Clinical Science
Clinical Science   |   May 1996
In Vitro sup 31 Phosphorus-Magnetic Resonance Spectroscopy of Muscle Extracts in Malignant Hyperthermia-susceptible Patients
Anesthesiology 5 1996, Vol.84, 1077-1082. doi:
Anesthesiology 5 1996, Vol.84, 1077-1082. doi:
Key words: Hyperthermia: malignant. Measurement techniques: phosphorus magnetic resonance spectroscopy. Muscle: perchloric acid extracts.
METABOLIC abnormalities in malignant hyperthermia-susceptible (MHS) patients have been reported in skeletal muscle using in vivo phosphorus magnetic resonance spectroscopy (sup 31 P-MRS). [1,2] It was recently reported that MHS patients also exhibited a higher phosphodiesters to phosphocreatine (PDE/PCr) ratio than did malignant hyperthermia-negative (MHN) patients in31Phosphorus spectra of gastrocnemius muscle at rest. [3,4] The significance of such a finding remains unknown. An increased PDE/PCr ratio also has been reported in patients with other myopathies using in vivo31P-MRS. [5,6] In vitro31P-MRS studies of the PDE compounds from normal muscle perchloric acid (PCA) extracts have identified the presence of glycerophosphorylcholine (GPC), [7,8] which is one water-soluble product of phospholipid catabolism. [9] Glycerophosphorylcholine content was increased in dystrophic chicken pectoralis muscle [7] as well as in slow twitch muscle containing type I fibers (e.g., in soleus muscle). [8] .
The aim of the current in vitro31P-MRS study was to analyze the PDE region from the muscle PCA extracts of vastus medialis of MHS and MHN patients with respect to the muscle fiber type composition. A higher GPC content in muscle PCA extracts of MHS patients could be a result of either a predominance of type I muscle fibers or an impairment of membrane phospholipid metabolism.
Materials and Methods
Human Muscle Biopsy
Muscle specimens from 17 patients referred to the Grenoble MH Diagnosis Center were studied. Muscle biopsy was performed because of a family history of MH or symptoms of MH during anesthesia. Open surgical biopsies of the vastus medialis muscles were performed under regional anesthesia. One or two muscle specimens 2-2.5 cm long and weighing 440 mg (270-1067 mg) were quickly frozen and stored in liquid nitrogen until the PCA extraction procedure. Other muscle specimens were processed for histologic analysis and for the contracture test, which was performed according to the European MH Group protocol. [10] The test was considered positive when the muscle specimens produced a sustained increase in baseline tension with an amplitude greater or equal to 0.2 g during application of both less or equal to 2% halothane and less or equal to 2 mM caffeine. The test was equivocal when a contracture was elicited by only one test substance. Other results were deemed MH-negative.
Perchloric Acid Extracts
The PCA extracts from muscle specimens were prepared as described previously, [11] within a 3-month period after biopsy. Briefly, the frozen biopsy specimen was pulverized with a liquid nitrogen-chilled mortar and pestled to a fine powder. The tissue was transferred and homogenized in a Potter-Elvehjem homogenizer with 0.6 mol l sup -1 of PCA (10 ml g sup -1 wet weight). After centrifugation at 41,400g for 10 min at 4 degrees C, the pH of the supernatant was adjusted to 6.6-7.0 with potassium hydroxide. This procedure was repeated twice, and the resulting supernatant was lyophilized. The powder was then resuspended in D2O solution (Laboratories Merck-Clevenot, Dardilly, France), centrifuged at 12,500g for 10 min and the supernatant was lyophilized. All the samples obtained after this PCA extraction procedure were stored in liquid nitrogen. Before the MRS experiment, the extract was resuspended in 350 micro liter D2O solution at pH 8.4 and centrifuged at 12,500g for 10 min.
sup 31 Phosphorus-Magnetic Resonance Spectroscopy Study
Magnetic resonance spectroscopic experiments were performed with a Bruker AM400 spectrometer (Bruker Spectrospin, Wissembourg, France) equipped with a 9.4-T, 89-mm diameter vertical bore magnet. The31Phosphorus spectra were acquired using a 5-mm diameter multi-nuclear probe tuned to31Phosphorus frequency (162.4 MHz) under the following conditions: single-pulse sequence of 15.5 micro second pulse length with a composite proton sequence decoupling; 4.05 s repetition time; 6 or 7 blocks of 1,600 scans; 16,384 data points per free induction decay; 6410-Hz spectral width; 3-Hz line broadening. The PCr was chosen as reference of chemical shift (0 ppm). The quantification was based on the integration of the peaks of phosphorylated compounds using UXNMR software (Bruker, Rheinstetten, Germany). Results were expressed as areas relative to the sum of PCr and inorganic phosphate (Pi) areas (PCr + Pi) or to the sum of the areas of all phosphorylated compounds visible by31P-MRS (Epsilon P).
Chemical Identification of the Phosphodiesters Peak
The following criteria were used to identify the chemical compounds present in the PDE region: (1) the correspondence between the observed chemical shifts in the muscle PCA extracts and the known chemical shifts for pure compounds at different pH values (titration experiment), (2) the persistence of a single spectral line of enhanced intensity on addition of a standard at a final concentration of 5 mg ml sup -1 to the PCA extract at more than one pH value (coresonance experiment). The standard compounds were L-alpha-glycerophosphoryl-ethanolamine, -inositol, -serine, -choline (GPC; Sigma, Saint-Quentin Fallavier, France).
Histologic Analysis
Sixteen muscle specimens were analyzed histologically by optical microscopy. Sections were cut on a freezing microtome and stained histochemically for myosin ATPase at pH 4.35 to perform the fiber type composition. The counting of fiber types and their mean diameters were determined using an image analyzer equipped with the Histo 200 software (Biocom, Lyon, France). The mean cross-sectional area of each muscle fiber type was then automatically calculated.
Statistical Analysis
Data were expressed as medians and ranges. The31P-MRS and histologic parameters of MHS and MHN groups were compared using the nonparametric Mann-Whitney U test at the 0.05 level of significance.
Results
The contracture tests revealed that seven patients (median 37 yr, range 16-63) were MHS and ten patients (median 23 yr, range 12-51) MHN. None were equivocal for responses to halothane or caffeine. Figure 1shows the PDE region in muscle PCA extract from an MHS patient, before and after sequential addition of PDE compounds. In the PDE region, a major peak was detected at 3.0 ppm. When standard compounds were added to the muscle PCA extract, there was an exact coincidence of the PDE peak only with the GPC standard (coresonance experiment). In addition, there were similar changes in the pH-dependent chemical shifts of the PDE peak of the muscle PCA extract spectrum, the pure GPC peak in D2O solution and the GPC peak when added to the muscle PCA extracts (Figure 2; titration experiment). The major peak in PDE region was thus assigned to GPC.
Figure 1. A coresonance experiment from a malignant hyperthermia-susceptible muscle muscle perchloric acid extract before (A) and after (B) sequential addition of phosphodiester standard compounds to assign the resonance of the phosphodiester region. The31Phosphorus spectra were acquired at 9.4 T with a 4.05-s pulse repetition rate. GPE = glycerophosphorylethanolamine; GPI = glycerophosphorylinositol; GPC = glycerophosphorylcholine; GPS = glycerophosphorylserine.
Figure 1. A coresonance experiment from a malignant hyperthermia-susceptible muscle muscle perchloric acid extract before (A) and after (B) sequential addition of phosphodiester standard compounds to assign the resonance of the phosphodiester region. The31Phosphorus spectra were acquired at 9.4 T with a 4.05-s pulse repetition rate. GPE = glycerophosphorylethanolamine; GPI = glycerophosphorylinositol; GPC = glycerophosphorylcholine; GPS = glycerophosphorylserine.
Figure 1. A coresonance experiment from a malignant hyperthermia-susceptible muscle muscle perchloric acid extract before (A) and after (B) sequential addition of phosphodiester standard compounds to assign the resonance of the phosphodiester region. The31Phosphorus spectra were acquired at 9.4 T with a 4.05-s pulse repetition rate. GPE = glycerophosphorylethanolamine; GPI = glycerophosphorylinositol; GPC = glycerophosphorylcholine; GPS = glycerophosphorylserine.
×
Figure 2. A titration experiment with the determination of chemical shifts, relative to the phosphocreatine as reference, of the phosphodiester compounds at different pH values, to assign the resonance of the phosphodiester region with respect to the pH-dependent chemical shifts. The chemical shifts of the major phosphodiester peak of the muscle extract spectrum were measured as well as those of pure phosphodiester compounds peaks in D2O solution and those when addition of phosphodiester standard compounds to the muscle perchloric acid extract.
Figure 2. A titration experiment with the determination of chemical shifts, relative to the phosphocreatine as reference, of the phosphodiester compounds at different pH values, to assign the resonance of the phosphodiester region with respect to the pH-dependent chemical shifts. The chemical shifts of the major phosphodiester peak of the muscle extract spectrum were measured as well as those of pure phosphodiester compounds peaks in D2O solution and those when addition of phosphodiester standard compounds to the muscle perchloric acid extract.
Figure 2. A titration experiment with the determination of chemical shifts, relative to the phosphocreatine as reference, of the phosphodiester compounds at different pH values, to assign the resonance of the phosphodiester region with respect to the pH-dependent chemical shifts. The chemical shifts of the major phosphodiester peak of the muscle extract spectrum were measured as well as those of pure phosphodiester compounds peaks in D2O solution and those when addition of phosphodiester standard compounds to the muscle perchloric acid extract.
×
Typical31Phosphorus spectra of muscle PCA extract obtained from MHN and MHS patients are shown in Figure 3. In these spectra, the GPC/(Pi + PCr) ratio was measurably higher in the muscle PCA extract of the MHS patient. For the two groups, the phosphomonoesters (PME) to Epsilon P (PME/Epsilon P), GPC/Epsilon P and GPC/(Pi + PCr) ratios were significantly higher in MHS muscle extracts than in MHN extracts (Figure 4and Table 1). The mean of the sum of ranks was 6.3 versus 12.8 for the PME/Epsilon P ratio, 6.8 versus 12.1 for the GPC/Epsilon P ratio, and 6.7 versus 12.3 for the GPC/(Pi/PCr) ratio in the MHS and MHN groups, respectively. There was no difference between the muscle specimens of MHS and MHN patients concerning the presence of type I fibers (43% [27.9-52.8] vs. 41.4% [28.3-50.5], respectively) and the mean cross-sectional area of type I fibers (3,019 micro2[2206-4657] vs. 2,734 micro2[1,257-3,217], respectively). None of the patients had specific myopathy on histologic examination of muscle specimens.
Figure 3.31Phosphorus-Magnetic resonance spectroscopic spectra of muscle muscle perchloric acid extract from malignant hyperthermia-negative patient (A) and malignant hyperthermia-susceptible patient (B). Spectra were acquired at 9.4 T in 7 x 1,600 scans (A) and in 6 x 1,600 scans (B) with a 4.05-s pulse repetition rate and processed with a 3-Hz exponential line broadening.
Figure 3.31Phosphorus-Magnetic resonance spectroscopic spectra of muscle muscle perchloric acid extract from malignant hyperthermia-negative patient (A) and malignant hyperthermia-susceptible patient (B). Spectra were acquired at 9.4 T in 7 x 1,600 scans (A) and in 6 x 1,600 scans (B) with a 4.05-s pulse repetition rate and processed with a 3-Hz exponential line broadening.
Figure 3.31Phosphorus-Magnetic resonance spectroscopic spectra of muscle muscle perchloric acid extract from malignant hyperthermia-negative patient (A) and malignant hyperthermia-susceptible patient (B). Spectra were acquired at 9.4 T in 7 x 1,600 scans (A) and in 6 x 1,600 scans (B) with a 4.05-s pulse repetition rate and processed with a 3-Hz exponential line broadening.
×
Figure 4. Distribution of the glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratios for malignant hyperthermia-susceptible and malignant hyperthermia-negative patients. The lines represent the median values for the two groups. There is a significantly higher glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratio in malignant hyperthermia-susceptible compared to malignant hyperthermia-negative subjects (*P < 0.05, Mann-Whitney U test).
Figure 4. Distribution of the glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratios for malignant hyperthermia-susceptible and malignant hyperthermia-negative patients. The lines represent the median values for the two groups. There is a significantly higher glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratio in malignant hyperthermia-susceptible compared to malignant hyperthermia-negative subjects (*P < 0.05, Mann-Whitney U test).
Figure 4. Distribution of the glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratios for malignant hyperthermia-susceptible and malignant hyperthermia-negative patients. The lines represent the median values for the two groups. There is a significantly higher glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratio in malignant hyperthermia-susceptible compared to malignant hyperthermia-negative subjects (*P < 0.05, Mann-Whitney U test).
×
Table 1. In Vitro Phosphorus Magnetic Resonance Spectroscopy Data of the Muscle Perchloric Acid Extracts in the Malignant Hyperthermia-susceptible and the Malignant Hyperthermia-negative Groups
Image not available
Table 1. In Vitro Phosphorus Magnetic Resonance Spectroscopy Data of the Muscle Perchloric Acid Extracts in the Malignant Hyperthermia-susceptible and the Malignant Hyperthermia-negative Groups
×
Discussion
A significantly higher relative concentration of GPC was found in muscle PCA extracts of the MHS patients as compared to the MHN patients. In the absence of histologic differences between muscle specimens of the two groups, these results suggest that GPC could be a marker of an impairment in the phospholipid metabolism in the skeletal muscle of MHS patients. However, there was an overlap between MHS and MHN values (Figure 4), limiting diagnostic potential of these in vitro results.
Each phosphorus-containing chemical group has a characteristic chemical shift position, which is determined by the molecular environment of the phosphorus atom contained within different phosphorylated compounds. However, ionic strength, pH, cationic, and protein concentration in cell compartments may complicate the assignment of a resonance peak recorded from intact tissue. Therefore, coresonance experiments at different pH levels are usually done to assign the resonances observed in31Phosphorus spectra of PCA extracts. [11,12] According to the PCA extract procedure, GPC was clearly identified as the primary component of the PDE peak in muscle PCA extract of MHS patients. The other PDE compounds appeared to be of minor contribution in muscle PCA extracts, as previously reported in normal muscle. [8] However, no absolute concentrations of GPC and other phosphorylated compounds were provided in the current study because of the absence of an external standard. In addition, the muscle specimens of different weights were resuspended in the same volume of D2O solution, leading to different signal-to-noise ratio between PCA extracts (Figure 3(A and B)). Internal references were thus chosen such as Epsilon Phosphorus and Pi + PCr, because there is a stoichiometric change between the decrease in the PCr peak intensity and the increase in the Pi peak intensity, so the sum Pi + PCr remains constant. When the PCA extract procedure is properly carried out, no water-soluble metabolites such as PCr, Pi, and GPC can be significantly lost by precipitation. [13] Finally, no significant difference in the sum of Pi and PCr has been found in quadriceps muscle between MHS and MHN patients. [14] .
Relative concentration of GPC was significantly elevated in the vastus medialis muscle extracts of MHS patients. This appears to be in accordance with the elevated PDE/PCr ratio observed in vivo in31Phosphorus spectra of the gastrocnemius muscle. [3,4] It has been reported that GPC is absent from the human biceps muscle, [7] a finding that could explain the discrepancy in the PDE peak between forearm and leg muscles found in MHS patients by in vivo31P-MRS. [1-4] Conversely, the highest concentration of GPC was found in slow twitch muscle containing type I fibers, e.g., in soleus muscle, and to a lesser extent, in the quadriceps muscle. [7,8] No difference in the percentage of type I fibers between MHS and MHN muscles was found in the current study, as previously reported in vastus lateralis muscle. [15] Because none of the patients had specific myopathy, these results suggest that the elevated GPC could be related to the MH susceptibility.
Glycerophosphorylcholine is a water-soluble metabolite produced by the catabolism of the membrane phospholipids, from the pathway of the phosphatidylcholine deacylation: production of lysophosphatidylcholine via phospolipase A2, followed by production of GPC via lysophospholipase. It has been suggested that GPC may regulate membrane phospholipid composition by acting on the enzyme lysophospholipase by a product inhibition. [16] An increase of GPC could thus result in an increase in lysophosphatidylcholine content, and consequently affect the membrane integrity. [9,17] This hypothesis could explain the general, although controversial, defect of membrane permeability in the MH syndrome. [18-20] However, similar levels of lysophosphatidylcholine and phosphatidylcholine have been found in vastus lateralis muscle between MHS and MHN patients. [21] In this way, an elevated GPC level could either imply an accelerated synthesis of phosphatidylcholine resulting in an accumulation of GPC, or a decreased hydrolysis of GPC. The determination of the enzymatic activities leading to the synthesis of phosphatidylcholine as well as to the degradation of GPC would thus be useful to elucidate the mechanisms that could account for the data.
The PME/Epsilon Phosphorus ratio was higher in the muscle PCA extracts of MHS patients than those of MHN patients. The phosphomonoesters include a number of compounds such as triose phosphates, hexose aliphatic phosphates, pentose phosphates, inosine and adenosine monophosphate, choline, and phosphoethanolamine. [12] However, no chemical identification of the PME region was performed in the current study and the significance of such results remains unknown.
These in vitro31P-MRS results demonstrate that the skeletal muscle of MHS patients exhibits a higher relative GPC content than that of MHN patients. Because this difference cannot be explained by histologic changes between MHS and MHN muscle specimens, these results suggest that GPC could be a marker of an impairment in the phospholipid metabolism in the skeletal muscle of MHS patients.
The authors thank J. Viret, the Department of Biophysics of The Military Health Research Center of Grenoble, for magnetic resonance spectroscopy facilities. They also thank Raphael Massarelli and Simon Doran, for their comments.
REFERENCES
Olgin J, Argov Z, Rosenberg H, Tuchler M, Chance B: Non-invasive evaluation of malignant hyperthermia susceptibility with phosphorus nuclear magnetic resonance spectroscopy. ANESTHESIOLOGY 1988; 68:507-13.
Olgin J, Rosenberg H, Allen G, Seestedt R, Chance B: A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility. Anesth Analg 1991; 72:36-47.
Payen JF, Bourdon L, Mezin P, Jacquot C, Le Bas JF, Stieglitz P, Benabid AL: Susceptibility to malignant hyperthermia detected noninvasively (letter). Lancet 1991; 337:1550-1.
Payen JF, Bosson JL, Bourdon L, Jacquot C, Le Bas JF, Stieglitz P, Benabid AL: Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with sup 31 Phosphorus-magnetic resonance spectroscopy. ANESTHESIOLOGY 1993; 78:848-55.
Newman RJ, Bore PJ, Chan L, Gadian DG, Styles P, Taylor D, Radda GK: Nuclear magnetic resonance studies of forearm in Duchenne dystrophy. Br Med J 1982; 284:1072-4.
Barany M, Siegel IM, Venkatasubramanian PN, Mok E, Wilbur AC: Human leg neuromuscular diseases: P-31 MR spectroscopy. Radiology 1989; 172:503-8.
Chalovich JM, Burt CT, Danon MJ, Glonek T, Barany M: Phosphodiesters in muscular dystrophies. Ann NY Acad Sci 1979; 317:649-68.
Burt CT, Glonek T, Barany M: Phosphorus-31 nuclear magnetic resonance detection of unexpected phosphodiesters in muscle. Biochemistry 1976; 15:4850-3.
Van den Bosch H: Phosphoglyceride metabolism. Ann Rev Biochem 1974; 43:243-77.
European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56:1267-9.
Remy C, Arus C, Ziegler A, Sam Lai E, Moreno A, Le Fur Y, Decorps M: In vivo, ex vivo and in vitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intracerebral glioma in rat brain: Assignment of resonances. J Neurochem 1994; 62:166-79.
Glonek T, Kopp SJ, Kot E, Pettegrew JW, Harrison WH, Cohen MM: P-31 nuclear magnetic resonance analysis of brain: The perchloric acid extract spectrum. J Neurochem 1982; 39:1210-9.
Barany M, Glonek T: Phosphorus-31 nuclear magnetic resonance of contractile systems, Methods in Enzymology: Structural and Contractile Proteins. Volume 85. Edited by Frederiksen DW and Cunningham LW, New York, Academic Press, 1982, pp 624-76.
Verburg MP, Britt BA, Oerlemans FTJJ, Scott B, Van Egmond J, De Bruijn CHMM: Comparison of metabolites in skeletal muscle biopsies from normal humans and those susceptible to malignant hyperthermia. ANESTHESIOLOGY 1986; 65:654-7.
Heiman-Patterson T, Fletcher JE, Rosenberg H, Tahmoush AJ: No relationship between fiber type and halothane contracture test results in malignant hyperthermia. ANESTHESIOLOGY 1987; 67:82-4.
Burt CT, Ribolow HJ: A hypothesis: Noncyclic phosphodiesters may play a role in membrane control. Biochem Med 1984; 31:21-30.
Sobel BE, Corr PB, Robison AK, Goldstein RA, Witkowski FX, Klein MS: Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest 1978; 62:546-53.
Ohnishi ST, Waring AJ, Fang SRG, Horiuchi K, Flick JL, Sadanaga KK, Ohnishi T: Abnormal membrane properties of the sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: Modes of action of halothane, caffeine, dantrolene, and two other drugs. Arch Biochem Biophys 1986; 247:294-301.
Ervasti JM, Mickelson JR, Lewis SM, Thomas DD, Louis CF: An electron paramagnetic resonance study of skeletal muscle membrane fluidity in malignant hyperthermia. Biochim Biophys Acta 1989; 986:70-4.
Rock E, Mammar MS, Vignon X, Thomas MA, Viret J: Abnormal fluidity state in membranes of malignant hyperthermia pig skeletal muscle. Arch Biochem Biophys 1990; 281:36-40.
Fletcher JE, Rosenberg H, Michaux K, Tripolitis L, Lizzo FH: Triglycerides, not phospholipids, are the source of elevated free fatty acids in muscle from patients susceptible to malignant hyperthermia. Eur J Anaesth 1989; 6:355-62.
Figure 1. A coresonance experiment from a malignant hyperthermia-susceptible muscle muscle perchloric acid extract before (A) and after (B) sequential addition of phosphodiester standard compounds to assign the resonance of the phosphodiester region. The31Phosphorus spectra were acquired at 9.4 T with a 4.05-s pulse repetition rate. GPE = glycerophosphorylethanolamine; GPI = glycerophosphorylinositol; GPC = glycerophosphorylcholine; GPS = glycerophosphorylserine.
Figure 1. A coresonance experiment from a malignant hyperthermia-susceptible muscle muscle perchloric acid extract before (A) and after (B) sequential addition of phosphodiester standard compounds to assign the resonance of the phosphodiester region. The31Phosphorus spectra were acquired at 9.4 T with a 4.05-s pulse repetition rate. GPE = glycerophosphorylethanolamine; GPI = glycerophosphorylinositol; GPC = glycerophosphorylcholine; GPS = glycerophosphorylserine.
Figure 1. A coresonance experiment from a malignant hyperthermia-susceptible muscle muscle perchloric acid extract before (A) and after (B) sequential addition of phosphodiester standard compounds to assign the resonance of the phosphodiester region. The31Phosphorus spectra were acquired at 9.4 T with a 4.05-s pulse repetition rate. GPE = glycerophosphorylethanolamine; GPI = glycerophosphorylinositol; GPC = glycerophosphorylcholine; GPS = glycerophosphorylserine.
×
Figure 2. A titration experiment with the determination of chemical shifts, relative to the phosphocreatine as reference, of the phosphodiester compounds at different pH values, to assign the resonance of the phosphodiester region with respect to the pH-dependent chemical shifts. The chemical shifts of the major phosphodiester peak of the muscle extract spectrum were measured as well as those of pure phosphodiester compounds peaks in D2O solution and those when addition of phosphodiester standard compounds to the muscle perchloric acid extract.
Figure 2. A titration experiment with the determination of chemical shifts, relative to the phosphocreatine as reference, of the phosphodiester compounds at different pH values, to assign the resonance of the phosphodiester region with respect to the pH-dependent chemical shifts. The chemical shifts of the major phosphodiester peak of the muscle extract spectrum were measured as well as those of pure phosphodiester compounds peaks in D2O solution and those when addition of phosphodiester standard compounds to the muscle perchloric acid extract.
Figure 2. A titration experiment with the determination of chemical shifts, relative to the phosphocreatine as reference, of the phosphodiester compounds at different pH values, to assign the resonance of the phosphodiester region with respect to the pH-dependent chemical shifts. The chemical shifts of the major phosphodiester peak of the muscle extract spectrum were measured as well as those of pure phosphodiester compounds peaks in D2O solution and those when addition of phosphodiester standard compounds to the muscle perchloric acid extract.
×
Figure 3.31Phosphorus-Magnetic resonance spectroscopic spectra of muscle muscle perchloric acid extract from malignant hyperthermia-negative patient (A) and malignant hyperthermia-susceptible patient (B). Spectra were acquired at 9.4 T in 7 x 1,600 scans (A) and in 6 x 1,600 scans (B) with a 4.05-s pulse repetition rate and processed with a 3-Hz exponential line broadening.
Figure 3.31Phosphorus-Magnetic resonance spectroscopic spectra of muscle muscle perchloric acid extract from malignant hyperthermia-negative patient (A) and malignant hyperthermia-susceptible patient (B). Spectra were acquired at 9.4 T in 7 x 1,600 scans (A) and in 6 x 1,600 scans (B) with a 4.05-s pulse repetition rate and processed with a 3-Hz exponential line broadening.
Figure 3.31Phosphorus-Magnetic resonance spectroscopic spectra of muscle muscle perchloric acid extract from malignant hyperthermia-negative patient (A) and malignant hyperthermia-susceptible patient (B). Spectra were acquired at 9.4 T in 7 x 1,600 scans (A) and in 6 x 1,600 scans (B) with a 4.05-s pulse repetition rate and processed with a 3-Hz exponential line broadening.
×
Figure 4. Distribution of the glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratios for malignant hyperthermia-susceptible and malignant hyperthermia-negative patients. The lines represent the median values for the two groups. There is a significantly higher glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratio in malignant hyperthermia-susceptible compared to malignant hyperthermia-negative subjects (*P < 0.05, Mann-Whitney U test).
Figure 4. Distribution of the glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratios for malignant hyperthermia-susceptible and malignant hyperthermia-negative patients. The lines represent the median values for the two groups. There is a significantly higher glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratio in malignant hyperthermia-susceptible compared to malignant hyperthermia-negative subjects (*P < 0.05, Mann-Whitney U test).
Figure 4. Distribution of the glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratios for malignant hyperthermia-susceptible and malignant hyperthermia-negative patients. The lines represent the median values for the two groups. There is a significantly higher glycerophosphorylcholine/(inorganic phosphate + phosphocreatine) ratio in malignant hyperthermia-susceptible compared to malignant hyperthermia-negative subjects (*P < 0.05, Mann-Whitney U test).
×
Table 1. In Vitro Phosphorus Magnetic Resonance Spectroscopy Data of the Muscle Perchloric Acid Extracts in the Malignant Hyperthermia-susceptible and the Malignant Hyperthermia-negative Groups
Image not available
Table 1. In Vitro Phosphorus Magnetic Resonance Spectroscopy Data of the Muscle Perchloric Acid Extracts in the Malignant Hyperthermia-susceptible and the Malignant Hyperthermia-negative Groups
×